- Eli Lilly and Company
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials
Indianapolis, August 17, 2010 (ots/PRNewswire) - Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary...
- 17.08.2010, 14:01:36
- /
- OTE0006
- Eli Lilly and Company
Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
Indianapolis, November 13 (ots/PRNewswire) -
- 13.11.2009, 15:11:41
- /
- OTE0006
Alle Aussendungen
Alle Anhänge
